Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome

NCT05089084 is registered in ClinicalTrials.gov with Arrowhead Pharmaceuticals as lead sponsor.

NCT NCT05089084
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05089084 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome
Lead sponsor
Arrowhead Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
December 14, 2021
Completion date
April 21, 2026
Enrollment
75 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

familial chylomicronemia